BioCentury | Feb 22, 2018
Preclinical News

New fluorination method expands medicinal chemistry toolbox

...experiments showed the catalyst more than doubled fluorination of multiple complex compounds, including the drugs nateglinide...
...compared with mild fluorinating agents alone. Novartis AG (NYSE:NVS; SIX:NOVN) markets Type II diabetes drug nateglinide...
BioCentury | Jun 5, 2014
Strategy

Sanford-Burnham goes fourth

...SGLT2) inhibitor Marketed for type 2 diabetes Mitsubishi Tanabe Pharma; Johnson & Johnson (NYSE:JNJ) Fastic/Starlix nateglinide...
BioCentury | May 6, 2013
Company News

Novartis pharmaceuticals news

...combination of amlodipine, a Ca channel blocker, and benazepril, an ACE inhibitor; diabetes drug Starlix nateglinide...
BioCentury | Nov 12, 2012
Company News

Ajinomoto, Astellas deal

...ended Sept. 30, Astellas said the companies partnered in October to conduct trials of Starsis nateglinide...
...of dipeptidyl peptidase-4 (DPP-4) . The companies could not be reached for details. Astellas markets Starsis...
BioCentury | Sep 13, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...nonfasted diabetic rats, the prodrugs, synthesized by conjugating NO-releasing chemical groups to the antidiabetic drugs nateglinide...
...anti-hyperglycemic activity comparable to that of the parent drugs. In the rat model, a lead nateglinide-derived...
...short-acting β cell-stimulating meglitinide, to treat diabetes. Novartis AG and Astellas Pharma Inc. market Starlix nateglinide...
BioCentury | Sep 19, 2011
Clinical News

Glucagon-like peptide-1 endocrine/metabolic data

...between 2004-09. Control therapies included Avandia rosiglitazone from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); Starlix nateglinide...
BioCentury | Mar 22, 2010
Clinical News

Diovan valsartan: Phase III data

...glucose tolerance and cardiovascular disease or risk factors receiving either once-daily Diovan or thrice-daily Starlix nateglinide...
...core (8.1% vs. 8.1%, p=0.42) and extended cardiovascular outcomes (14.5% vs. 14.8%, p=0.22) vs. placebo. Starlix...
...the 3 co-primary endpoints vs. placebo. Specifically, the cumulative incidence of diabetes was 36% for Starlix...
BioCentury | Mar 16, 2010
Clinical News

Novartis reports NAVIGATOR data

...reported data from the Phase III NAVIGATOR trial of once-daily Diovan valsartan and thrice-daily Starlix nateglinide...
...co-primary endpoints of significantly reducing the incidence of core and extended cardiovascular outcomes vs. placebo. Starlix...
...molecule angiotensin II receptor (type AT1) antagonist, to treat high blood pressure. The pharma markets Starlix...
BioCentury | May 8, 2008
Cover Story

A gut feeling

...II Pancreas Amylin/Eli Lilly Byetta exenatide Glucagon-like peptide-1 (GLP-1) receptor agonist Diabetes Marketed Novartis Starlix nateglinide...
BioCentury | Mar 10, 2008
Regulation

Time & numbers

...1999, not including insulins or insulin analogs. The number of patients for Januvia, Byetta and Starlix...
...months 137-150 (295) 29 weeks plus extension [150E] Astellas (Tokyo:4503) / Novartis (NYSE:NVS; SWX:NOVN) Starlix nateglinide...
Items per page:
1 - 10 of 32